JP2016056206A5 - - Google Patents

Download PDF

Info

Publication number
JP2016056206A5
JP2016056206A5 JP2016005132A JP2016005132A JP2016056206A5 JP 2016056206 A5 JP2016056206 A5 JP 2016056206A5 JP 2016005132 A JP2016005132 A JP 2016005132A JP 2016005132 A JP2016005132 A JP 2016005132A JP 2016056206 A5 JP2016056206 A5 JP 2016056206A5
Authority
JP
Japan
Prior art keywords
glucosidase
glycogenosis
type
acid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016005132A
Other languages
English (en)
Japanese (ja)
Other versions
JP6163216B2 (ja
JP2016056206A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016056206A publication Critical patent/JP2016056206A/ja
Publication of JP2016056206A5 publication Critical patent/JP2016056206A5/ja
Application granted granted Critical
Publication of JP6163216B2 publication Critical patent/JP6163216B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2016005132A 2000-07-18 2016-01-14 Ii型糖原病の治療 Expired - Lifetime JP6163216B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
US60/219,237 2000-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014141336A Division JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017099515A Division JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療

Publications (3)

Publication Number Publication Date
JP2016056206A JP2016056206A (ja) 2016-04-21
JP2016056206A5 true JP2016056206A5 (https=) 2016-12-15
JP6163216B2 JP6163216B2 (ja) 2017-07-12

Family

ID=22818451

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2002511773A Expired - Lifetime JP5113312B2 (ja) 2000-07-18 2001-07-10 Ii型糖原病の治療
JP2007312804A Pending JP2008081507A (ja) 2000-07-18 2007-12-03 Ii型糖原病の治療
JP2011173569A Pending JP2012006953A (ja) 2000-07-18 2011-08-09 Ii型糖原病の治療
JP2013162201A Expired - Lifetime JP5792774B2 (ja) 2000-07-18 2013-08-05 Ii型糖原病の治療
JP2014141336A Pending JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療
JP2016005132A Expired - Lifetime JP6163216B2 (ja) 2000-07-18 2016-01-14 Ii型糖原病の治療
JP2017099515A Pending JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療
JP2017201250A Pending JP2018002749A (ja) 2000-07-18 2017-10-17 Ii型糖原病の治療
JP2018171154A Pending JP2018199721A (ja) 2000-07-18 2018-09-13 Ii型糖原病の治療
JP2019202851A Pending JP2020019822A (ja) 2000-07-18 2019-11-08 Ii型糖原病の治療

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2002511773A Expired - Lifetime JP5113312B2 (ja) 2000-07-18 2001-07-10 Ii型糖原病の治療
JP2007312804A Pending JP2008081507A (ja) 2000-07-18 2007-12-03 Ii型糖原病の治療
JP2011173569A Pending JP2012006953A (ja) 2000-07-18 2011-08-09 Ii型糖原病の治療
JP2013162201A Expired - Lifetime JP5792774B2 (ja) 2000-07-18 2013-08-05 Ii型糖原病の治療
JP2014141336A Pending JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017099515A Pending JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療
JP2017201250A Pending JP2018002749A (ja) 2000-07-18 2017-10-17 Ii型糖原病の治療
JP2018171154A Pending JP2018199721A (ja) 2000-07-18 2018-09-13 Ii型糖原病の治療
JP2019202851A Pending JP2020019822A (ja) 2000-07-18 2019-11-08 Ii型糖原病の治療

Country Status (17)

Country Link
US (10) US7056712B2 (https=)
EP (4) EP1301201B1 (https=)
JP (10) JP5113312B2 (https=)
AT (1) ATE355075T1 (https=)
AU (3) AU7194101A (https=)
BR (1) BR0113006A (https=)
CA (1) CA2416492C (https=)
CY (2) CY1120977T1 (https=)
DE (1) DE60126947T2 (https=)
DK (5) DK1301201T3 (https=)
ES (5) ES2599401T3 (https=)
LT (3) LT3449934T (https=)
MX (1) MXPA03000474A (https=)
PT (5) PT1782825E (https=)
SI (3) SI3108895T1 (https=)
TW (1) TWI280882B (https=)
WO (1) WO2002005841A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7194101A (en) * 2000-07-18 2002-01-30 Univ Duke Treatment of glycogen storage disease type ii
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
ES2535461T3 (es) * 2008-07-08 2015-05-11 Duke University Método de tratamiento de la enfermedad por almacenamiento de glucógeno
EP2475376B1 (en) * 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
EP2981551B1 (en) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Methods and compositions for treatment of pompe disease
CN105377039A (zh) * 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
WO2016178431A1 (ja) * 2015-05-07 2016-11-10 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
EP3344337A4 (en) * 2015-08-31 2019-03-06 Duke University METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
IL325155A (en) 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
DK1137762T3 (da) 1998-12-07 2009-02-02 Genzyme Corp Behandling af Pompes sygdom
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
AU7194101A (en) * 2000-07-18 2002-01-30 Univ Duke Treatment of glycogen storage disease type ii
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Similar Documents

Publication Publication Date Title
JP2016056206A5 (https=)
JP2013231081A5 (https=)
JP2011528896A5 (https=)
JP2013155188A5 (https=)
JP2016539156A5 (https=)
JP2016514132A5 (https=)
Gane et al. Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor: LB-19
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
JP2014513722A5 (https=)
JP2011528897A5 (https=)
RU2018103081A (ru) Способы лечения колитов
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP2018509388A5 (https=)
JP2015517511A5 (https=)
RU2018125622A (ru) Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза
ZA202210024B (en) Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
IL274512B1 (en) Igg stimulated remyelination of peripheral nerves
JP2016538840A5 (https=)
JP2013100370A5 (https=)
Scheerens et al. Treatment with MEMP1972A, an anti-M1 prime monoclonal antibody, reduced serum IgE in healthy volunteers and patients with allergic rhinitis
JP2018522881A5 (https=)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
MD3803G2 (ro) Metodă de tratament al hiperchineziilor la copii
JP2017530142A5 (https=)